Advanced And Recurrent Ovarian Cancer

The FDA approved olaparib in combination with abiraterone acetate and prednisone or prednisolone for men with suspected deleterious or deleterious BRCA-mutated metastatic castration-resistant prostate cancer.

A trial designed to evaluate maveropepimut-S for women with advanced recurrent ovarian cancer demonstrated encouraging activity, according to the agent’s manufacturer.